Tracey Lodie is to join Quell Therapeutics Ltd as chief scientific officer, to be based in Boston, Mass, US. The UK company has a pipeline of autologous T-regulatory cell therapies with plans to expand into allogeneic products as well. She joins Quell from Gamida Cell Ltd, where she served as CSO. Dr Lodie began her career at Sanofi-Genzyme where she became senior director of immunology. Dr Lodie holds a PhD in immunology and pathology from Boston University School of Medicine and completed her postdoctoral work in haematology/oncology at Harvard Medical School, US.
Quell Therapeutics announced the appointment on 29 July 2021.
Copyright 2021 Evernow Publishing Ltd
